Sign in

CLRB on Nasdaq

Cellectar Biosciences, Inc.

In its 2026 annual report the company says: “We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects.”4 It is headquartered in Madison, United States.2 Its shares trade on Nasdaq under the symbol CLRB.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerCLRB on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersMadison, United States2
  • Incorporated inDE3
  • Business address100 Campus Drive, Florham Park, Nj 079323
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493000NFZCRG7BYQV932
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER, 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 26370732

See how the biggest companies compare on our leaderboards

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income5678910-$23.0M in 2025+62% since 2019
-$60.0M-$40.0M-$20.0M02019: -$14.2M-$14.2M20192020: -$15.3M-$15.3M2020+8%2021: -$24.1M-$24.1M2021+58%2022: -$28.8M-$28.8M2022+19%2023: -$39.0M-$39.0M2023+35%2024: -$51.8M-$51.8M2024+33%2025: -$23.0M-$23.0M2025−56%
Net income5678910-$21.8M in 2025+55% since 2019
-$60.0M-$40.0M-$20.0M02019: -$14.1M-$14.1M20192020: -$15.1M-$15.1M2020+7%2021: -$24.1M-$24.1M2021+60%2022: -$31.8M-$31.8M2022+32%2023: -$42.8M-$42.8M2023+35%2024: -$44.6M-$44.6M2024+4%2025: -$21.8M-$21.8M2025−51%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$11.5M$26.1M
General and administrative$11.5M$25.6M
Total operating expenses$23.0M$51.8M
LOSS FROM OPERATIONS-$23.0M-$51.8M
Warrant issuance expense-$7.7M
Gain on valuation of warrants$753.7K$13.8M
Interest income$435.1K$1.2M
Total other income (expense), net$1.2M$7.3M
LOSS BEFORE INCOME TAXES-$21.8M-$44.5M
INCOME TAX PROVISION (BENEFIT)$66.0K
NET LOSS-$21.8M-$44.6M
NET LOSS PER SHARE - BASIC (In dollars per share)-$8.35-$36.52
NET LOSS PER SHARE - DILUTED (In dollars per share)-$8.35-$41.89
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC (In shares)2.6M shares1.2M shares
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - DILUTED (In shares)2.6M shares1.2M shares

Compare Cellectar Biosciences, Inc. with another company

Corporate structure

Cellectar Biosciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cellectar Biosciences, Inc.

  • Cellectar Biosciences, Inc. Madison, Wisconsin, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cellectar Biosciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$1.2M10 Dec 31, 2025$1.0M10 Dec 31, 2024+15.8%
Property and equipment, net$549.4K10 Dec 31, 2025$757.1K10 Dec 31, 2024−27.4%
Operating-lease assets (leased space)$360.7K10 Dec 31, 2025$436.9K10 Dec 31, 2024−17.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$13.2M10 Dec 31, 2025$23.3M10 Dec 31, 2024−43.3%

Properties, in its own words

We lease administrative office space in Florham Park, New Jersey and Middleton, Wisconsin. On December 30, 2022, we entered into an Amended Agreement of Lease (the “Amended Lease”), with Campus 100 LLC for the Florham Park space. The space in New Jersey consists of approximately 4,000 square feet and is rented for approximately $12,100 per month under an agreement that expires on April 30, 2029, subject to one additional five-year extension. The space in Wisconsin consists of approximately 300 square feet and is rented for approximately $3,400 per month under an ongoing agreement.

Item 2 of the 10-K filed Mar 4, 2026.4

Leadership

Who has led Cellectar Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Simon Pedder2014
  2. James Caruso V.2015–now

President

  1. Simon Pedder2014
  2. James Caruso V.2015–now

Chief financial officer

  1. Chad J. Kolean2014–2018
  2. Brian M. Posner2018–2019
  3. Charles Thomas Bernhardt Iii.2019
  4. Dov Elefant2019–2022

Chief operating officer

  1. Jarrod Longcor2023–now
201520202025
Board members and other officers (21)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorAsher Alban Chanan-Kahn named Sep 22, 202338

Former names

  • NOVELOS THERAPEUTICS, INC.Feb 28, 2005 to Feb 11, 20143
  • COMMON HORIZONS INCJun 4, 2004 to Jun 2, 20053

Timeline

  1. Aug 13, 20268-K Results of operations39
  2. Jul 10, 20268-K Executive or director change; Shareholder vote40
  3. May 18, 20268-K Executive or director change41
  4. May 14, 20268-K Results of operations42
  5. May 8, 20268-K Entered a material agreement; Unregistered sale of shares; Other events43
  6. Mar 4, 20268-K Results of operations44
  7. Nov 13, 20258-K Results of operations45
  8. Oct 10, 20258-K Entered a material agreement; Results of operations; Unregistered sale of shares46
  9. Oct 6, 20258-K Regulation FD disclosure; Other events47
  10. Aug 14, 20258-K Results of operations48
  11. Jun 26, 20258-K Other events49
  12. Jun 25, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed50
  13. Aug 4, 2015New chief executive James Caruso V. becomes CEO13
  14. Aug 18, 2014New chief executive Simon Pedder becomes CEO14
  15. Jun 24, 1996Founded Cellectar Biosciences, Inc. is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.41) a share, on Nov 13, 2025.51

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results39
  2. May 14, 2026Reported quarterly or annual results42
  3. Mar 4, 2026Reported quarterly or annual results44
  4. Nov 13, 2025Reported quarterly or annual results45
  5. Oct 10, 2025Reported quarterly or annual results46
  6. Aug 14, 2025Reported quarterly or annual results48
  7. May 13, 2025Reported quarterly or annual results52
  8. Mar 13, 2025Reported quarterly or annual results53

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

269 filings to the SEC since October 2021: 9 annual reports, 16 quarterly reports, 72 major events, 64 insider forms, 43 large holders, 1 private raises, 64 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G EDGAR
  2. Aug 14, 2026SCHEDULE 13G EDGAR
  3. Aug 14, 2026SCHEDULE 13G EDGAR
  4. Aug 14, 2026SCHEDULE 13G EDGAR
  5. Aug 13, 2026SCHEDULE 13G EDGAR
  6. Aug 13, 20268-K EDGAR
  7. Aug 13, 202610-Q EDGAR
  8. Aug 4, 2026SCHEDULE 13G EDGAR
  9. Jul 10, 20264/A OWNERSHIP DOCUMENT EDGAR
  10. Jul 10, 20268-K EDGAR
  11. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  15. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  18. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  19. Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
  20. Jun 9, 20263 OWNERSHIP DOCUMENT EDGAR

The 269 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 6 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 7, 2026Longcor JarrodChief Operating OfficerBuy8,680$2.88$25.0KForm 4
May 7, 2026CARUSO JAMES VPresident & CEOBuy8,680$2.88$25.0KForm 4
Dec 12, 2025NEIS JOHNDirectorSale198$3.70$733Form 4
Jul 2, 2025CARUSO JAMES VPresident & CEOBuy10,000$4.99$49.9KForm 4
Jul 2, 2025Longcor JarrodChief Operating OfficerBuy10,000$4.99$49.9KForm 4
Jul 2, 2025Kolean Chad JCFOBuy5,000$4.99$24.9KForm 4
Jan 10, 2025Longcor JarrodChief Operating OfficerBuy30,000$0.28$8.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025James V. Caruso67$1.1M73
2025Jarrod Longcor53$767.0K73
2025Chad J. Kolean61$620.4K73
2024President and Chief Executive Officer$3.0M73
2024Chief Operating Officer$1.8M73
2024Chief Financial Officer$1.2M73

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$24.7M 2020–2023
Money received by yearMoney received by year, 2020–2023: $24.7M in all. Private raises (Form D) $24.5M; PPP loans $184.0K.$0$10M$20M$30M2020 · PPP loans: $184.0K2020202120222023 · Private raises (Form D): $24.5M2023
Figures by year
YearPrivate raises (Form D)PPP loansTotal
2023$24.5M–$24.5M
2020–$184.0K$184.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Sep 8, 2023Raised $24.5 million in a private offering of equity38 Form D: 21 investors so far Form D

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA74. Matched to this company by name and state.

  1. Apr 10, 2020$184.0K PPP loan (first draw) from BMO Bank National Association74To CELLECTAR BIOSCIENCES, INC., Florham Park NJ; $185.3K forgiven Dec 31, 2020

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Caligan Partners LP469,998$1.3M0.1%New
Nantahala Capital Management, LLC439,996$1.2M0.0%New
Stempoint Capital LP354,938$986.7K0.2%New
Vanguard Capital Management LLC327,367$910.1K0.0%+245,483
Silverarc Capital Management, LLC321,728$894.4K0.1%New
Bleichroeder LP288,679$802.5K0.1%+188,679
Jupiter Topco LLC274,156$759.4K0.0%New
Balyasny Asset Management L.P.220,000$611.6K0.0%New
Empery Asset Management, LP189,605$527.1K0.6%New
Diadema Partners LP138,341$384.6K0.1%New
Stonepine Capital Management, LLC104,550$290.6K0.2%New
Persistent Asset Partners Ltd92,983$258.5K0.1%New
Boothbay Fund Management, LLC85,069$236.5K0.0%New
Geode Capital Management, LLC53,351$148.3K0.0%+573
Vanguard Fiduciary Trust Co46,220$128.5K0.0%+29,647
Sequoia Financial Advisors, LLC21,850$60.7K0.0%+3,000
Riverview Capital Advisers, LLC10,384$50.1K0.0%No change
Northern Trust Corp14,839$41.3K0.0%New
BlackRock, Inc.4,735$13.2K0.0%−10
UBS Group AG3,093$8.6K0.0%−6,554
Barclays PLC561$1.6K0.0%New
Morgan Stanley510$1.4K0.0%No change
TD Waterhouse Canada Inc.63$1780.0%No change
Acadian Asset Management LLC16,577$460.0%New
SBI Securities Co., Ltd.11$310.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Cellectar Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCellectar Biosciences, Inc.1
  • CIK0001279704
  • Employer ID (EIN)04-33218044
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address100 Campus Drive, Florham Park, NJ 079321
  • Phone(608) 441-81201
  • Shares outstanding9,452,108 as of Aug 11, 202612
  • Public float$12.8M as of Jun 30, 20254
  • AuditorDeloitte & Touche LLP, Morristown, New Jersey PCAOB ID 34; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJun 21, 20041
  • Filings1,216 in all: 8-K (403), 4 (175), 424B3 (94), 10-Q (56), CORRESP (47), UPLOAD (41), EFFECT (38), SC 13G/A (37)1
    All 56 form types

    3 (29), SC 13G (28), S-1/A (23), S-1 (20), 10-K (18), DEF 14A (18), PRE 14A (15), POS AM (13), SCHEDULE 13G (11), SCHEDULE 13G/A (11), DEFA14A (10), 10-K/A (9), 10QSB (9), 424B5 (9), D (8), S-3 (8), SB-2/A (8), 424B4 (6), FWP (5), NT 10-Q (5), S-8 (5), 4/A (4), 424B1 (4), 8-K/A (4), SB-2 (4), 10KSB (3), ARS (3), S-3/A (3), 10-Q/A (2), 25-NSE (2), 3/A (2), 8-A12B (2), CERTNAS (2), DEFR14A (2), PRER14A (2), REGDEX (2), REGDEX/A (2), S-1MEF (2), SC 13D (2), SC 13D/A (2), 10KSB/A (1), 10QSB/A (1), 5 (1), CT ORDER (1), D/A (1), DRS (1), NT 10-K (1), RW (1)

  • Latest filingsAnnual report (10-K) Mar 4, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) May 28, 2026
    Latest 8-K (8-K) Aug 13, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.00001CLRBNasdaq

From the cover page of the 10-K filed Mar 4, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Cellectar Biosciences, Inc. names in Item 1A of its 10-K filed Mar 4, 2026: 41 risks under these headings, as written.4

  • Risks Related to Capital and Our Operations
  • We will require additional capital in order to continue our operations and may have difficulty raising additional capital.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • Risks Related to Manufacturing and Supply
  • We rely on a collaborative outsourced business model, and disruptions with our third-party collaborators may impede our ability to gain marketing approval from the FDA, the European Commission (based on recommendation from the EMA), or other regulatory authorities and delay or impair commercialization of any products.
  • Risks Related to Research, Development and Regulatory Approval of Our Product Candidates
  • All of our product candidates are in clinical development or in preclinical development. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.
  • Failure to complete the development of our technologies, obtain government approvals, including required FDA approvals, or comply with ongoing governmental regulations could prevent, delay or limit introduction or sale of proposed products and result in failure to achieve revenues or maintain our ongoing business.
  • We may seek Breakthrough Therapy designation by the FDA for one or more of our product candidates, which we may not receive. Such designation may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.
  • Fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure FDA approval of our product candidates.
  • The FDA has granted rare pediatric disease designation, RPDD, to iopofosine for treatment of neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma and osteosarcoma; however, we may not be able to realize any value from such designation.
  • Clinical studies involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.
The other 32 risks
  • We may be required to suspend or discontinue clinical studies because of unexpected side effects or other safety risks that could preclude approval of our product candidates.
  • The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to change, including to judicial challenges.
  • Risks Related to Legal Compliance and Litigation
  • Controls we or our third-party collaborators have in place to ensure compliance with all applicable laws and regulations may not be effective.
  • We are exposed to product, clinical and preclinical liability risks that could create a substantial financial burden should we be sued.
  • Risks Related to Intellectual Property
  • We expect to rely on our patents as well as specialized regulatory designations such as orphan drug classification for our product candidates, but regulatory drug designations may not confer marketing exclusivity or other expected commercial benefits.
  • We may face litigation from third parties claiming our products infringe on their intellectual property rights, particularly because there is often substantial uncertainty about the validity and breadth of medical patents.
  • If we are unable to adequately protect or enforce our rights to intellectual property or to secure rights to third-party patents, we may lose valuable rights, experience reduced market share, assuming any, or incur costly litigation to protect our intellectual property rights.
  • Risks Related to Our Employees
  • We rely on a small number of key personnel who may terminate their employment with us at any time, and our success will depend on our ability to hire additional qualified personnel.
  • Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete.
  • We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their current or former employers.
  • Risks Related to Commercialization of our Products
  • Acceptance of our products in the marketplace is uncertain and failure to achieve market acceptance will prevent or delay our ability to generate revenues.
  • Regulatory approval for any approved product is limited by the FDA, the European Commission (based on recommendation from the EMA), and comparable foreign authorities, to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and we may incur significant liability if it is determined that we are promoting the “off-label” use of any of our future product candidates if approved.
  • If any of our third-party contractors fail to perform their responsibilities to comply with FDA rules and regulations, the marketing and sales of our products could be delayed and we may be subject to enforcement action, which could decrease our revenues.
  • If manufacturers obtain approval for generic versions of our products, once approved, or of products with which we compete, our business may be harmed.
  • Unforeseen safety issues could emerge with our products, once approved, that could require us to change the prescribing information to add warnings, limit use of the product, and/or result in litigation. Any of these events could have a negative impact on our business.
  • The market for our proposed products is rapidly changing and competitive, and new therapeutics, drugs and treatments that may be developed by others could impair our ability to develop our business or become competitive.
  • As a result of continued changes in marketing, sales and distribution, we may be unsuccessful in our efforts to sell our proposed products, develop a direct sales organization, or enter into relationships with third parties.
  • If we are unable to convince physicians of the benefits of our intended products, we may incur delays or additional expense in our attempt to establish market acceptance.
  • If our products are unable to obtain adequate reimbursement from third-party payors, or if additional healthcare reform measures are adopted, it could hinder or prevent the commercial success of our product candidates.
  • Enacted and future legislation may increase the difficulty and cost for us to commercialize our product candidates and may affect the prices we may set.
  • We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and other federal and state healthcare laws, and the failure to comply with such laws could result in substantial penalties. Our employees, independent contractors, consultants, principal investigators, CROs, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • Regulatory legislative reform measures may have a material adverse effect on our business.
  • Risks Related to Internal Controls
  • We identified certain misstatements to our previously issued financial statements and have restated the financial statements described below, which has exposed us to additional risks and uncertainties.
  • We identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and share price.
  • Risks Related to Our Equity Securities
  • Failure to meet Nasdaq’s continued listing requirements could result in the delisting of our common stock, negatively impact the price of our common stock and negatively impact our ability to raise additional capital.
  • Our stock price has experienced, and may continue to experience, price fluctuations.
  • Our common stock could be further diluted as the result of the issuance of additional shares of common stock, convertible securities, warrants or options.
  • Provisions of our certificate of incorporation, by-laws, and Delaware law may make an acquisition of us or a change in our management more difficult.
  • General Risk Factors
  • Conflicts, military actions, terrorist attacks, natural disasters. public health crises, including the occurrence of a contagious disease or illness, cyber-attacks and general instability could adversely affect our business.
  • War, terrorism, other acts of violence, or natural or manmade disasters may affect the markets in which we operate, our patients and resources required in our research and development activities.
  • Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.
  • Failure to meet investor and stakeholder expectations regarding environmental, social and corporate governance, or “ESG” matters may damage our reputation.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
    SEC EDGAROther events
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74